These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8107325)

  • 1. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Nov; 63(3):319-25. PubMed ID: 8107325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis.
    Kawasaki T; Katoh M; Kaku S; Gushima H; Takenaka T; Yui Y; Kawai C
    Jpn J Pharmacol; 1993 Sep; 63(1):9-16. PubMed ID: 8271535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator, in a photochemically induced platelet-rich thrombosis model.
    Kawasaki T; Kaku S; Takenaka T; Yanagi K; Ohshima N
    J Cardiovasc Pharmacol; 1994 Jun; 23(6):884-9. PubMed ID: 7523779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):834-40. PubMed ID: 7509901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi.
    Suzuki M; Funatsu T; Tanaka H; Usuda S
    Jpn J Pharmacol; 1998 Jul; 77(3):177-83. PubMed ID: 9717764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experimental model of carotid artery thrombosis in rats and the thrombolytic activity of YM866, a novel modified tissue-type plasminogen activator.
    Kawasaki T; Kawamura S; Katoh S; Takenaka T
    Jpn J Pharmacol; 1993 Oct; 63(2):135-42. PubMed ID: 8283822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi.
    Suzuki S; Saito M; Suzuki N; Kato H; Nagaoka N; Yoshitake S; Mizuo H; Yuzuriha T; Yui Y; Kawai C
    J Cardiovasc Pharmacol; 1991 May; 17(5):738-46. PubMed ID: 1713988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis.
    Kawasaki T; Kaku S; Sakai Y; Takenaka T
    J Pharm Pharmacol; 1996 Oct; 48(10):1041-8. PubMed ID: 8953506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single bolus administration of recombinant tissue plasminogen activator: effects on infarct related vessel patency, microvascular perfusion, and microvascular reocclusion in a canine model of thrombotic occlusion/reperfusion.
    Longridge DJ; Follenfant MJ; Ford AJ
    Cardiovasc Res; 1991 Mar; 25(3):184-91. PubMed ID: 1903080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: comparison with urokinase-induced coronary thrombolysis.
    Susawa T; Yui Y; Hattori R; Takahashi M; Aoyama T; Takatsu Y; Sakaguchi K; Yui N; Kawai C
    Jpn Circ J; 1987 Apr; 51(4):431-5. PubMed ID: 2441082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of thrombolysis with single-chain and two-chain recombinant tissue-type plasminogen activators in canine coronary thrombosis.
    Yokoyama M; Ichikawa Y; Yatani A; Matsui K; Nakahara H; Kaneko M; Sakurama T; Ueshima S; Matsuo O
    J Cardiovasc Pharmacol; 1996 Oct; 28(4):571-5. PubMed ID: 8891884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intravenous bolus injection or continuous infusion of recombinant single chain urokinase-type plasminogen activator (saruplase) for thrombolysis. A canine model of combined coronary arterial and femoral venous thrombosis.
    Rapold HJ; Wu ZM; Stassen T; Van de Werf F; Collen D
    Blood; 1990 Oct; 76(8):1558-63. PubMed ID: 2119830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of heparin and systemic lysis on coronary blood flow after reperfusion induced by the novel recombinant plasminogen activator BM 06.022 in a canine model of coronary thrombosis.
    Martin U; Fischer S; Sponer G
    J Am Coll Cardiol; 1993 Sep; 22(3):914-20. PubMed ID: 8354832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative thrombolytic properties of tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (u-PA) and K1K2Pu (a t-PA/u-PA chimera) in a combined arterial and venous thrombosis model in the dog.
    Lu HR; Wu Z; Pauwels P; Lijnen HR; Collen D
    J Am Coll Cardiol; 1992 May; 19(6):1350-9. PubMed ID: 1342779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ventricular function and cardiac hypertrophy after coronary thrombolysis with tissue-type plasminogen activator (t-PA) in dogs with coronary artery thrombi.
    Suzuki M; Asano H; Kimoto A; Tanaka H; Usuda S
    J Pharm Pharmacol; 2000 Aug; 52(8):969-76. PubMed ID: 11007068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K; Kloner RA
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue type plasminogen activator in coronary thrombosis.
    Nicolini FA; Nichols WW; Saldeen TG; Mehta JL
    Cardiovasc Res; 1991 Apr; 25(4):283-9. PubMed ID: 1909212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant lys-plasminogen given before, but not after, recombinant tissue-type plasminogen activator markedly improves coronary thrombolysis in dogs: relationship of thrombolytic efficacy with parameters of fibrinolysis.
    Chen LY; Nichols WW; Saldeen TG; Mehta JL
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):283-9. PubMed ID: 8720429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
    Gu SA; Ducas J; Wolfe K; Patton JN; Prewitt RM
    Chest; 1991 Jul; 100(1):201-6. PubMed ID: 1905615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.